The first patient in cohort 4 has been dosed in the ongoing phase 1 OPTIC trial of ADVM-022, according to a press release from Adverum Biotechnologies.
Nine patients with wet age-related macular degeneration will receive a single intravitreal injection of ADVM-022 at a dose of 6 × 1011 vg/eye as well as a subsequent steroid eye drop prophylaxis for 6 weeks.
“We believe that utilizing the higher dose of ADVM-022 with the use of steroid eye drop prophylaxis will further support that our gene therapy candidate, ADVM-022, has the potential to be an important treatment option for patients living with wet age-related macular degeneration,” Aaron Osborne, MBBS, chief medical oﬃcer of Adverum, said in the release.
In addition, Osborne said clinical trial sites have implemented extra safety precautions for patients and staff, which have allowed enrollment to continue.
The company expects to share data from the four cohorts later this year.